Literature DB >> 7672686

Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease.

N Arber1, S Berliner, A Hallak, Y Bujanover, I Dotan, E Liberman, M Santo, M Moshkowitz, J Ratan, G Dotan.   

Abstract

The aim of the study was to determine the comparative usefulness of inflammatory markers, in evaluating disease activity in patients with inflammatory bowel disease. Disease activity was assessed by the Mayo Clinic score for ulcerative colitis, and Harvey-Bradshaw score for Crohn's disease. Five hundred normal blood donors who had no underlying inflammatory condition served as controls. The erythrocyte sedimentation rate, platelet and white blood cell count, C reactive protein, and the leucocyte adhesiveness/aggregation test (LAAT) were determined in each patient. One hundred and twenty four patients with inflammatory bowel disease were tested while in remission and 128 in relapse. Their mean (SD) per cent of aggregated white blood cells in the peripheral blood was 8 (5) and 17 (10) respectively compared with controls 6 (4) (p < 0.0001). Moreover, the LAAT could effectively discriminate between various grades of disease activity, the values in patients with active disease being 13 (6)% in mild, 17 (10)% in moderate, and 26 (10)% in severe disease (p < 0.0001). Other acute phase reactants including the erythrocyte sedimentation rate, the white blood cell count, the platelet count, neutrophil count, as well as, the C reactive protein concentration did not differentiate as well between the various groups. Using logistic regression analysis to differentiate between inflammatory bowel disease patients in remission or relapse, the LAAT was the single best indicator. The addition of any other test did not contribute to the discrimination. Among the different laboratory variables tested only the LAAT significantly discriminated between the five different subgroups of controls, remission and mild, moderate or severe disease activity.

Entities:  

Mesh:

Year:  1995        PMID: 7672686      PMCID: PMC1382772          DOI: 10.1136/gut.37.1.77

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG.

Authors:  K B Jensen; S Jarnum; G Koudahl; M Kristensen
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

3.  The induction of augmented granulocyte adherence by inflammation. Mediation by a plasma factor.

Authors:  A L Lentnek; A D Schreiber; R R MacGregor
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

4.  Circulating immune complexes and disease activity in Crohn's disease.

Authors:  R Fiasse; A Z Lurhuma; C L Cambiaso; P L Masson; C Dive
Journal:  Gut       Date:  1978-07       Impact factor: 23.059

5.  Serum alpha 1-acid glycoprotein in chronic ulcerative colitis.

Authors:  W H Dearing; W F McGuckin; L R Elveback
Journal:  Gastroenterology       Date:  1969-02       Impact factor: 22.682

6.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

7.  Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.

Authors:  C Andre; L Descos; P Landais; J Fermanian
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

8.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

9.  An index of inflammatory activity in patients with Crohn's disease.

Authors:  P A van Hees; P H van Elteren; H J van Lier; J H van Tongeren
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

10.  Serum lysozyme in Crohn's disease and ulcerative colitis.

Authors:  C A Helman; B H Novis; S Bank; L Wormold; P Jacobs
Journal:  S Afr Med J       Date:  1977-12-17
View more
  4 in total

1.  Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study.

Authors:  D Ludwig; S Wiener; A Brüning; K Schwarting; G Jantschek; K Fellermann; M Stahl; E F Stange
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease.

Authors:  M Göke; J C Hoffmann; J Evers; H Krüger; M P Manns
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  Superiority of a functional leukocyte adhesiveness/aggregation test over the white blood cell count to discriminate between mild and significant inflammatory response in patients with acute bacterial infections.

Authors:  Ori Rogowski; Rivka Rotstein; David Zeltzer; Sarit Misgav; Daniel Justo; Daniel Avitzour; Tamar Mardi; Jacob Serov; Nadir Arber; Shlomo Berliner; Itzhak Shapira
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

4.  A subgroup of first-degree relatives of Crohn's disease patients shows a profile of inflammatory markers in the blood which is more typical of Crohn's disease patients than of normal individuals.

Authors:  Broide Efrat; Goren Iris; Hongbin Wang; Scapa Eitan; Keisari Yona
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.